Antigenics Receives Key Patents Expanding Its Immunology Platforms [pulled from the SI:News page for AGEN]
NEW YORK, Jun 21, 2001 /PRNewswire via COMTEX/ -- Antigenics Inc. (Nasdaq: AGEN chart, msgs) announced today that it was issued a U.S. patent (No. 6,231,859) that will expand the scope of potential applications for the company's Stimulon(R) family of adjuvants. The patent covers novel combinations of the QS-21 immune adjuvant
with additional saponin adjuvants resulting in synergistic adjuvant activity. In dose optimization studies, it has been found that a combination of low dose QS-21 and QS-7, an adjuvant active fraction of Quillaja saponaria, has the same beneficial immune effect as conventional doses of QS-21, but results in a milder vaccine formulation than
does QS-21 alone. Such combinations may be useful for vaccine formulations that have stringent requirement for reactogenicity, such as pediatric vaccines.
[snip]
Regards,
Harry J. |
